Cassava Sciences announces 2023 scientific goals

The company said, "In Q2 2023, we expect to complete patient dosing for our on-going Cognition Maintenance Study, in which over 100 patients with mild-to-moderate Alzheimer’s disease are randomized to simufilam or placebo for six months. In Q3 2023, we expect to announce top-line results of the Cognition Maintenance Study.In Q4 2023, we expect to complete patient enrollment for both of our Phase 3 studies. Mid-year 2023, we expect an independent, third party to present evidential data for the biological activity of simufilam outside the field of neurodegeneration. Mid-year 2023, we expect an independent, third party to generate new data for SavaDx using mass spectrometry."